Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
3 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
EBV BCL-2 homologue BHRF1 drives chemoresistance and lymphomagenesis by inhibiting multiple cellular pro-apoptotic proteins.
Cell Death Differ. 2020 May;27(5):1554-1568. doi: 10.1038/s41418-019-0435-1. Epub 2019 Oct 23.
Cell Death Differ. 2020.
PMID: 31645677
Free PMC article.
BCL-XL inhibition by BH3-mimetic drugs induces apoptosis in models of Epstein-Barr virus-associated T/NK-cell lymphoma.
Sejic N, George LC, Tierney RJ, Chang C, Kondrashova O, MacKinnon RN, Lan P, Bell AI, Lessene G, Long HM, Strasser A, Shannon-Lowe C, Kelly GL.
Sejic N, et al.
Blood Adv. 2020 Oct 13;4(19):4775-4787. doi: 10.1182/bloodadvances.2020002446.
Blood Adv. 2020.
PMID: 33017468
Free PMC article.
Item in Clipboard
First-in-human clinical trial of allogeneic, platelet-derived extracellular vesicles as a potential therapeutic for delayed wound healing.
Johnson J, Law SQK, Shojaee M, Hall AS, Bhuiyan S, Lim MBL, Silva A, Kong KJW, Schoppet M, Blyth C, Ranasinghe HN, Sejic N, Chuei MJ, Tatford OC, Cifuentes-Rius A, James PF, Tester A, Dixon I, Lichtfuss G.
Johnson J, et al. Among authors: sejic n.
J Extracell Vesicles. 2023 Jul;12(7):e12332. doi: 10.1002/jev2.12332.
J Extracell Vesicles. 2023.
PMID: 37353884
Free PMC article.
Clinical Trial.
Item in Clipboard
Cite
Cite